SCHEMBL1977856

SCHEMBL1977856

O=C(c1ccc(OCc2ccccc2)cc1)N1CCC1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A7 Q99884 1/20 0.70
ALDH1A1 P00352 6/20 0.69
NPC1 O15118 5/20 0.69
RAB9A P51151 5/20 0.69
MAPT P10636 3/20 0.69
CASP3 P42574 1/20 0.68
SENP8 Q96LD8 1/20 0.68
SENP7 Q9BQF6 1/20 0.68
SENP6 Q9GZR1 1/20 0.68
HSD17B10 Q99714 1/20 0.62
NAAA Q02083 1/20 0.62
NR4A1 P22736 1/20 0.62
NR4A2 P43354 1/20 0.62
NR4A3 Q92570 1/20 0.62
SMN1; SMN2 Q16637 4/20 0.61
TP53 P04637 2/20 0.61
LMNA P02545 2/20 0.61
HTT P42858 1/20 0.61
RECQL P46063 1/20 0.61
HPGD P15428 5/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15420889 0.96 NPC1 (0.76) SLC6A7ALDH1A1NPC1RAB9AMAPT
SCHEMBL11081153 0.88 SLC6A7 (0.61) SLC6A7ALDH1A1NPC1RAB9AMAPT
SCHEMBL5851806 0.87 SLC6A7 (0.66) SLC6A7ALDH1A1NPC1RAB9AMAPT
SCHEMBL1169664 0.87 HRH3 (0.61) SLC6A7ALDH1A1NPC1RAB9AMAPT
Ethylene SCHEMBL8377795 0.85 SLC6A7 (0.63) SLC6A7ALDH1A1NPC1RAB9AMAPT
SCHEMBL4736708 0.84 SLC6A7 (0.65) SLC6A7ALDH1A1NPC1MAPTNAAA
SCHEMBL27965228 0.83 SMN1; SMN2 (0.75) SLC6A7ALDH1A1NPC1RAB9AMAPT
SCHEMBL27965232 0.82 ALDH1A1 (0.66) SLC6A7ALDH1A1NPC1RAB9AMAPT
SCHEMBL15949477 0.82 SLC6A7 (0.63) SLC6A7ALDH1A1NPC1RAB9AMAPT
SCHEMBL7519290 0.82 SLC6A7 (0.63) SLC6A7ALDH1A1NPC1MAPTNAAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8609699-B2 Oxotetrahydrofuran-2-yl-benzimidazole derivative MSD K.K. (JP) 2013-12-17 US disclosed
EP-2328892-B1 OXOTETRAHYDROFURAN-2-YL-BENZIMIDAZOLE DERIVATIVE MSD KK (JP) 2013-01-16 EP disclosed
US-20110144162-A1 OXOTETRAHYDROFURAN-2-YL-BENZIMIDAZOLE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2011-06-16 US disclosed
EP-2328892-A1 OXOTETRAHYDROFURAN-2-YL-BENZIMIDAZOLE DERIVATIVE MSD K.K. (JP) 2011-06-08 EP disclosed
WO-2010024110-A1 OXOTETRAHYDROFURAN-2-YL-BENZIMIDAZOLE DERIVATIVE BANYU PHARMACEUTICAL CO.,LTD. (JP) 2010-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144162-A1 OXOTETRAHYDROFURAN-2-YL-BENZIMIDAZOLE DERIVATIVE GCK, GCKR, KHK SLC6A7 2534/4885ALDH1A1 823/4885NPC1 2556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.